BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leblanc K, Bell AD, Ezekowitz JA, Tan MK, Laflamme D, Goldin L, Habert J, Lin PJ, Saunders K, Ngui D, Ng AP, Desroches J, Goodman SG; for the OPTIMAL AF Investigators. Non‐vitamin K antagonist oral anticoagulant (NOAC) use and dosing in Canadian practice: Insights from the optimising pharmacotherapy in the management approach to lowering risk in atrial fibrillation (OPTIMAL AF) Programme. Int J Clin Pract 2020;74. [DOI: 10.1111/ijcp.13625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Carlin S, Eikelboom JW. Direct oral anticoagulant dose selection: Challenging cases. J Thromb Haemost 2021;19:2680-6. [PMID: 34558172 DOI: 10.1111/jth.15536] [Reference Citation Analysis]
2 Carlin S, Bond A, Gross P, Bell A, Douketis J, Geerts W, Galanaud JP. Initiation of anticoagulation in atrial fibrillation by primary care physicians: Results of a telephone survey. Thromb Res 2021;202:176-81. [PMID: 33872825 DOI: 10.1016/j.thromres.2021.04.004] [Reference Citation Analysis]
3 Lemesle G, Bauters C, Bonello L, Fauchier L, Cayla G, Marijon E, Guenoun M, Schurtz G, Ninni S, Richardson M, Albert F, Cohen S, Lamblin N, Danchin N. Management of antithrombotics in situations with a gap in evidence: A national French survey focusing on patients with coronary artery disease and atrial fibrillation. Int J Cardiol 2021:S0167-5273(21)01966-5. [PMID: 34864080 DOI: 10.1016/j.ijcard.2021.11.077] [Reference Citation Analysis]